AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian _target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways
- PMID: 21993994
- PMCID: PMC3269553
- DOI: 10.1002/hep.24736
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian _target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways
Abstract
Activation of v-akt murine thymoma viral oncogene homolog (AKT) and Ras pathways is often implicated in carcinogenesis. However, the oncogenic cooperation between these two cascades in relationship to hepatocellular carcinoma (HCC) development remains undetermined. To investigate this issue, we generated a mouse model characterized by combined overexpression of activated forms of AKT and neuroblastoma Ras viral oncogene homolog (N-Ras) protooncogenes in the liver by way of hydrodynamic gene transfer. The molecular mechanisms underlying crosstalk between AKT and N-Ras were assessed in the mouse model and further evaluated in human and murine HCC cell lines. We found that coexpression of AKT and N-Ras resulted in a dramatic acceleration of liver tumor development when compared with mice overexpressing AKT alone, whereas N-Ras alone did not lead to tumor formation. At the cellular level, concomitant up-regulation of AKT and N-Ras resulted in increased proliferation and microvascularization when compared with AKT-injected mice. Mechanistic studies suggested that accelerated hepatocarcinogenesis driven by AKT and N-Ras resulted from a strong activation of mammalian _target of rapamycin complex 1 (mTORC1). Furthermore, elevated expression of FOXM1/SKP2 and c-Myc also contributed to rapid tumor growth in AKT/Ras mice, yet by way of mTORC1-independent mechanisms. The biological effects of coactivation of AKT and N-Ras were then recapitulated in vitro using HCC cell lines, which supports the functional significance of mTORC1, FOXM1/SKP2, and c-Myc signaling cascades in mediating AKT and N-Ras-induced liver tumor development.
Conclusion: Our data demonstrate the in vivo crosstalk between the AKT and Ras pathways in promoting liver tumor development, and the pivotal role of mTORC1-dependent and independent pathways in mediating AKT and Ras induced hepatocarcinogenesis.
Copyright © 2011 American Association for the Study of Liver Diseases.
Figures
Similar articles
-
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.Hepatology. 2015 Jan;61(1):200-13. doi: 10.1002/hep.27396. Epub 2014 Nov 25. Hepatology. 2015. PMID: 25145583 Free PMC article.
-
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.Gastroenterology. 2008 Oct;135(4):1322-32. doi: 10.1053/j.gastro.2008.07.012. Epub 2008 Jul 17. Gastroenterology. 2008. PMID: 18722373 Free PMC article.
-
V-AKT murine thymoma viral oncogene homolog/mammalian _target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.Hepatology. 2012 May;55(5):1473-84. doi: 10.1002/hep.25600. Epub 2012 Apr 4. Hepatology. 2012. PMID: 22271091
-
Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.J Hepatol. 2013 Oct;59(4):830-41. doi: 10.1016/j.jhep.2013.04.031. Epub 2013 May 7. J Hepatol. 2013. PMID: 23665184 Review.
-
[EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].Pathologe. 2014 Nov;35 Suppl 2:177-84. doi: 10.1007/s00292-014-2007-y. Pathologe. 2014. PMID: 25394965 Review. German.
Cited by
-
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.Acta Pharmacol Sin. 2015 Feb;36(2):241-51. doi: 10.1038/aps.2014.122. Epub 2015 Jan 5. Acta Pharmacol Sin. 2015. PMID: 25557114 Free PMC article.
-
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.Nat Commun. 2021 Jun 9;12(1):3500. doi: 10.1038/s41467-021-23864-9. Nat Commun. 2021. PMID: 34108491 Free PMC article.
-
ZBTB7B is a permissive regulator of hepatocellular carcinoma initiation by repressing c-Jun expression and function.Cell Death Dis. 2024 Jan 15;15(1):55. doi: 10.1038/s41419-024-06441-y. Cell Death Dis. 2024. PMID: 38225233 Free PMC article.
-
_targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma.Pharmaceutics. 2023 Aug 14;15(8):2130. doi: 10.3390/pharmaceutics15082130. Pharmaceutics. 2023. PMID: 37631344 Free PMC article. Review.
-
MicroRNA-206 promotes the recruitment of CD8+ T cells by driving M1 polarisation of Kupffer cells.Gut. 2022 Aug;71(8):1642-1655. doi: 10.1136/gutjnl-2021-324170. Epub 2021 Oct 27. Gut. 2022. PMID: 34706869 Free PMC article.
References
-
- Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215–219. - PubMed
-
- Spangenberg HC, Thimme R, Blum HE. _targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2009;6:423–432. - PubMed
-
- Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130:1117–1128. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous